The present invention relates to a pharmaceutical composition including a
CDK inhibitor and an ID2 activator for the prevention or treatment of
bladder cancer, wherein based on the finding that: among CDK1-TFCP2L1 pathway targets associated with urothelial differentiation in
bladder cancer cells, ID2 is a factor significantly correlating with the tumor grade of
bladder cancer; an ID2 activator exhibits a
therapeutic effect on bladder
cancer; and the combined administration of CDK1 inhibitor and ID2 activator induces
apoptosis of bladder
cancer cells and significantly suppresses the invasiveness of
cancer cells, compared to administration thereof alone, thereby exhibiting a
therapeutic effect of remarkably suppressing the size and progression of bladder cancer, a composition comprising a
CDK inhibitor and an ID2 activator and a method for combined administration thereof are provided as novel therapeutic means for the prevention or treatment of bladder cancer.